This is a preview of subscription content, log in via an institution to check access.
Literatur
Chavez-MacGregor M, Zhang N, Buchholz TA et al (2013) Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 31:4222–4228 (=Originalbeitrag")
Halyard MY, Pisansky TM, Dueck AC et al (2009) Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol 27:2638–2644
Erven K, Florian A, Slagmolen P et al (2013) Subclinical cardiotoxicity detected by strain rate imaging up to 14 months after breast radiation therapy. Int J Radiat Oncol Biol Phys 85:1172–1178
Darby SC, Ewertz M, McGale P et al (2013) Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368:987–998
Petersen C, Würschmidt F (2011) Late toxicity of radiotherapy: a problem or a challenge for the radiation oncologist? Breast Care (Basel) 6:369–374
Lohr F, Heggemann F, Papavassiliu T et al (2009) Is cardiotoxicity still an issue after breast-conserving surgery and could it be reduced by multifield IMRT? Strahlenther Onkol 185:222–230
Wieshammer S, Dreyhaupt J, Müller D et al (2013) Cardiotoxicity and cancer therapy: treatment-related cardiac morbidity in patients presenting with symptoms suggestive of heart or lung disease. Oncology 85:137–144
Einhaltung ethischer Richtlinien
Interessenkonflikt. F. Pohl gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pohl, F. Signifikante Kardiotoxizität von Trastuzumab bei der adjuvanten Systemtherapie älterer Patientinnen mit Mammakarzinom. Strahlenther Onkol 190, 699–700 (2014). https://doi.org/10.1007/s00066-014-0683-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00066-014-0683-4